The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|September 22, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 1
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 1:
A 65-year-old man with stage IV NSCLC.
- Tissue biopsy showed EGFR+ adenocarcinoma
- The patient was enrolled in a clinical trial of erlotinib vs erlotinib/bevacizumab
- He was treated with erlotinib for 10 months before developing asymptomatic progression, with slowly growing lesions.
- He was continued on erlotinib for 3 more months; His next scan showed rapid progression.
- Repeat bronchoscopy and mutation testing showed an acquired EGFR T790M mutation
- Patient was subsequently switched to osimertinib
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5